In this episode, Dennis Walker and Mikaela de la Myco dive into the intersection of sex and psychedelics and discuss her experiences with sacred intimacy, indigenous Mexican ceremony, and womb care facilitation.
In this episode, Christi provides insight into how ketamine impacts people’s physical and mental health. She goes into the comparison of ketamine’s effects compared to other psychedelics and how Flow Integrative’s patient care is unique.
The mental healthcare crisis is escalating: Are Psychedelic Medicines the Solution? Can psychedelics health North America fight against anxiety, depression and addiction?
It is well known that during these unprecedented times of lockdowns and fear, our society’s mental health has taken a toll. Unfortunately, few realize how dire the situation has become.
In some respects, this pandemic has accelerated other health care crises: such as the addiction and overdose crisis, the depression crisis, and the anxiety crisis.
These crises can be hard to see when the illnesses are often hidden by those that are experiencing them, out of shame.
However, we can’t start talking about solutions to the problem until we see how big the problem is.
Therefore, in this episode, we are going to take a look at:
1. Some of the data regarding addiction, depression, and anxiety levels during the pandemic, and show you how stark this increase has been;
2. We will discuss a novel solution which has a lot of evidence backing it up: using psychedelics like magic mushrooms and LSD to treat these maladies of the mind;
Enjoy the episode!
Timestamps:
0:00 – Intro
1:37 – Increased rates of Anxiety, Depression & Addiction in North America
6:24 – Psychedelic inspired medicines – potential solutions?
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Links:
Rates of addiction since the epidemic began:
https://www.kten.com/story/44309290/continued-increase-in-substance-abuse-after-pandemic
Rates of overdose:
https://www.google.com/url?q=https://www.forbes.com/sites/niallmccarthy/2021/07/16/us-experiences-a-historic-spike-in-overdose-deaths-infographic/?sh5452ed443650&sa=D&source=editors&ust=1626828792173000&usg=AOvVaw3NuNLOX7F8X_pg9Uh0Rnhv
Rates of depression:
https://www.meetfieldtrip.com/news/news-details/2021/More-than-80-of-Americans-report-one-or-more-symptoms-of-depression-and-many-have-turned-to-substances-to-cope-with-negative-emotions-during-COVID-19-Pandemic-according-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx
https://www.nature.com/articles/d41586-021-00175-z
Research into psychedelics as potential alternative treatments
Psilocybin: A potential treatment for depression:
https://newatlas.com/health-wellbeing/psilocybin-therapy-major-depression-trial-results-johns-hopkins/
https://www.imperial.ac.uk/news/219413/magic-mushroom-compound-performs-well-antidepressant/
Psilocybin : A potential cure for Smoking:
https://pubmed.ncbi.nlm.nih.gov/27441452/
Ibogaine: A potential cure for addiction:
https://www.tandfonline.com/doi/full/10.1080/00952990.2017.1310218
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#ANXIETY#DEPRESSION #PsychedelicTherapy
This week on the Psychedelic Spotlight podcast, we’re chatting with Dr. Erica Zelfand. She is a family doctor specializing in integrative and functional family medicine. She’s also a ketamine prescriber, facilitator of therapeutic experiences, and a medical writer and public speaker.
In today’s episode, we discuss the results of the much awaited phase 2b clinical trial using psilocybin (comp360) to treat treatment-resistant-depression. This Compass Pathways (Nasdaq: CMPS) trial is so important for a couple of reasons: first, it is the largest ever psychedelics clinical trial, with 219 people completing the trial; and second because it is the furthest progressed psilocybin trial ever, being in phase 2b.
So what did the results say? Can Magic Mushrooms treat depression? Can Psychedelics help Mental Health?
Well, the results are mixed. About a quarter of the people who underwent Compass Pathways psychedelic therapy program, who received 25 mg of psilocybin (Comp 360), entered remission after 12 weeks. And almost a third of individuals in this group saw their depression symptoms decrease by 50% or more, as measured by the MADRS scale. This is more than double the success rate for the control group, showing strong significant effects of psilocybin therapy on depression. Therefore, it is clear that psychedelics like psilocybin CAN help mental health… at least somewhat
However, many, myself included, were hoping for stronger results, such as the MDMA to treat PTSD phase 3 results that MAPS released earlier this year. This led to disappointment at the positive results, as they were not as game changing as we had hoped.
In this episode, we describe Compass Pathways’ psilocybin for depression clinical trial, explain the results, and then try to put said results into context. We finish by looking towards the future, and discussing where Compass Pathways, and other psychedelic medicines companies like MindMed, Cybin and Small Pharma, should go from here.
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Links:
Compass Results: https://ir.compasspathways.com/static-files/0f9fbce8-2619-438b-a6ba-5bbe2ba08cf6
Montgomery-Asberg Depression Rating Scale (MADRS):
https://en.wikipedia.org/wiki/Montgomerysberg_Depression_Rating_Scale
MAPS MDMA-PTSD Study:
https://www.nytimes.com/2021/05/03/health/mdma-approval.html
Comp 360 Open Label Study:
https://www.globenewswire.com/en/news-release/2021/10/20/2317456/0/en/Open-label-study-of-COMP360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups.html
MindMed Psilocybin SSRI Study:
https://mindmed.co/news/press-release/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-rd-collaboration/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #psilocybin #depression
Buy your tickets to the Benzinga Psychedelics Capital Conference on…
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
